Array Biopharma Inc (ARRY) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.19. The company posted revenue of $43.20 million in the period, compared to analysts expectations of $41.70 million. The company’s revenue was up 251.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
Array Biopharma Inc closed down -0.14 points or -3.32% at $4.08 with 35,37,203 shares getting traded on Tusday. Post opening the session at $4.22, the shares hit an intraday low of $4.06 and an intraday high of $4.22 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on May 12, 2015, Charles M Baum (director) sold 25,000 shares at $7.38 per share price. According to the SEC, on Mar 4, 2015, Kyle Lefkoff (director) sold 70,000 shares at $8.00 per share price. On Mar 4, 2015, Andrews R Robbins (SVP, Commercial Operations) sold 21,576 shares at $8.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials is indicated for Kinesin spindle protein (KSP) inhibitor for MM; ARRY-797 in Phase II clinical trials indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials indicated for CRTh2 antagonist for asthma and ARRY-614 in Phase I clinical trials is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition the Company has 11 ongoing partner-funded clinical programs including two MEK inhibitors which are both in Phase III clinical trials binimetinib with Novartis and selumetinib with AstraZeneca.